FATE THERAPEUTICS INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
FATE THERAPEUTICS INC (FATE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- FATE THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.52M, a 50.82% decline year-over-year.
- FATE THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.93M, a 46.77% decline year-over-year.
- FATE THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $4.86M, a 58.68% decline year-over-year.
- FATE THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $7.15M, a 25.71% decline year-over-year.
- FATE THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $24.92M, a 39.94% decline from fiscal 2024.
- FATE THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $41.50M, a 4.52% decline from fiscal 2023.
- FATE THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $43.46M, a 44.80% decline from fiscal 2022.
- FATE THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $78.73M, a 44.83% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.52M 10-Q · filed 2026-08-13 | $7.45M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $3.93M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $24.92M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $4.86M 10-Q · filed 2025-11-13 | $12.02M derived: sum of 2 quarters · filed 2026-08-13 | $19.40M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $7.15M 10-Q · filed 2026-08-13 | $14.54M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $7.38M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $41.50M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $11.77M 10-Q · filed 2025-11-13 | $21.39M derived: sum of 2 quarters · filed 2025-11-13 | $32.38M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $9.63M 10-Q · filed 2025-11-13 | $20.61M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $10.98M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $43.46M 10-K · filed 2025-03-05 | |||
| 2023-09-30 | $10.10M 10-Q · filed 2024-11-12 | $23.00M derived: sum of 2 quarters · filed 2024-11-12 | $33.98M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $12.90M 10-Q · filed 2024-11-12 | $23.88M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $10.98M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $78.73M 10-K · filed 2024-02-26 | |||
| 2022-09-30 | $19.47M 10-Q · filed 2023-11-08 | $40.01M derived: sum of 2 quarters · filed 2023-11-08 | $59.34M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $20.54M 10-Q · filed 2023-11-08 | $39.87M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $19.33M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $54.36M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $13.54M 10-Q · filed 2021-11-04 | $26.79M derived: sum of 2 quarters · filed 2022-11-03 | $39.77M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $13.25M 10-Q · filed 2022-11-03 | $26.23M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $12.98M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $30.75M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $7.84M 10-Q · filed 2021-11-04 | $15.08M derived: sum of 2 quarters · filed 2021-11-04 | $21.99M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $7.24M 10-Q · filed 2021-11-04 | $14.15M derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $6.91M 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $17.41M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $4.57M 10-Q · filed 2020-11-05 | $8.96M derived: sum of 2 quarters · filed 2020-11-05 | $12.83M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $4.39M 10-Q · filed 2020-11-05 | $8.25M derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $3.87M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $6.29M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $1.64M 10-Q · filed 2019-11-05 | $3.13M derived: sum of 2 quarters · filed 2019-11-05 | $4.51M derived: sum of 3 quarters · filed 2019-11-05 | |
| 2018-06-30 | $1.49M 10-Q · filed 2019-11-05 | $2.87M derived: sum of 2 quarters · filed 2019-11-05 | ||
| 2018-03-31 | $1.38M 10-Q · filed 2019-11-05 | |||
| 2017-12-31 | $3.61M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | $871.00K 10-Q · filed 2018-11-01 | $1.84M derived: sum of 2 quarters · filed 2018-11-01 | $2.71M derived: sum of 3 quarters · filed 2018-11-01 | |
| 2017-06-30 | $973.00K 10-Q · filed 2018-11-01 | $1.84M derived: sum of 2 quarters · filed 2018-11-01 | ||
| 2017-03-31 | $867.00K 10-Q · filed 2018-11-01 | |||
| 2016-12-31 | $3.18M 10-K · filed 2019-03-05 | |||
| 2015-12-31 | $2.40M 10-K · filed 2018-03-05 | |||
| 2014-12-31 | $2.43M 10-K · filed 2017-03-16 | |||
| 2013-12-31 | $1.55M 10-K · filed 2016-03-03 | |||
| 2012-12-31 | $155.00K 10-K · filed 2015-03-12 | |||
| 2011-12-31 | $172.00K 10-K · filed 2014-03-17 | |||
| 2010-12-31 | $229.00K 10-K · filed 2014-03-17 | |||
| 2009-12-31 | $196.00K 10-K · filed 2014-03-17 | |||
| 2008-12-31 | $17.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |